Helix Biopharma Corp.
HBP.TO provides healthcare diagnostics services and operates in the Biotechnology & Medical Research industry.
Business. HBP.TO is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through product sales and is primarily listed on the Toronto Stock Exchange under the ticker HBP.TO. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
HBP.TO is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through product sales and is primarily listed on the Toronto Stock Exchange under the ticker HBP.TO. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
HBP.TO has a weak capital structure and liquidity position, as indicated by a negative net cash position after subtracting total debt. The company's debt-to-equity ratio is 0.02, suggesting minimal leverage, but its current ratio of 0.13 indicates significant short-term liquidity risk. The company's free cash flow is negative at -5.2 million CAD, and operating cash flow is also negative at -3.8 million CAD, further highlighting its cash flow challenges.
Profitability metrics are negative, with a return on equity of -33.4% and a return on assets of -27.68%. These figures are below the industry median for Biotechnology & Medical Research, indicating underperformance relative to peers. The company reported a net loss of 5.2 million CAD and an operating loss of 5.4 million CAD, which is a concern for investors.
The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification. This could expose the company to higher operational and market risks if a single segment or region underperforms.
Growth trajectory is uncertain, as the company has not provided forward-looking revenue guidance. Historical data shows a consistent pattern of losses, with no clear indication of a turnaround. The absence of a positive growth outlook and the lack of capital expenditure (only -2,000 CAD) suggest limited investment in future capacity or innovation.
Risk factors include medium liquidity risk and low dilution potential. The company's negative net cash position and lack of disclosed capital raising activities suggest a limited ability to fund operations without external financing. No dilution sources are identified in the available documents, but the company's financial position could necessitate future equity or debt offerings.
Recent events include the latest financial filing, which shows continued losses and negative cash flows. No recent earnings call transcripts or material events are disclosed in the available data, limiting insight into management's strategy or operational updates.
- HBP.TO has a weak capital structure and liquidity position, with a negative net cash position and high short-term liquidity risk.
- The company is unprofitable, with a return on equity of -33.4% and a return on assets of -27.68%.
- Revenue concentration and segment exposure are not disclosed, suggesting a lack of diversification.
- Growth trajectory is uncertain, with no forward-looking guidance and limited capital expenditure.
- Liquidity risk is medium, and dilution potential is low, but the company may need to raise capital in the future.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- HBP.TO Market data — financials · 2026-05-28